Plus Therapeutics, Inc.
PSTV
$0.59
-$0.03-4.84%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.49% | -14.43% | 18.54% | 52.63% | 113.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.49% | -14.43% | 18.54% | 52.63% | 113.20% |
| Cost of Revenue | -25.66% | 1.09% | 9.18% | 23.84% | 14.09% |
| Gross Profit | 48.65% | -28.97% | 0.44% | -3.41% | 23.01% |
| SG&A Expenses | 14.25% | 24.12% | 16.33% | -5.76% | -11.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.77% | 11.99% | 12.53% | 8.47% | 0.78% |
| Operating Income | 9.44% | -25.50% | -10.31% | 2.54% | 16.43% |
| Income Before Tax | -43.82% | -130.36% | 2.54% | 15.03% | 22.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.82% | -130.36% | 2.54% | 15.03% | 22.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.82% | -130.36% | 2.54% | 15.03% | 22.92% |
| EBIT | 9.44% | -25.50% | -10.31% | 2.54% | 16.43% |
| EBITDA | 9.78% | -26.12% | -10.08% | 2.92% | 17.07% |
| EPS Basic | -894.63% | -866.42% | 54.09% | 60.86% | 62.03% |
| Normalized Basic EPS | -1,176.84% | -1,139.03% | 54.09% | 60.86% | 62.02% |
| EPS Diluted | -817.49% | -874.04% | 48.29% | 56.63% | 58.79% |
| Normalized Diluted EPS | -1,259.11% | -1,133.42% | 58.05% | 63.75% | 64.25% |
| Average Basic Shares Outstanding | 248.12% | 55.79% | 111.43% | 125.06% | 108.34% |
| Average Diluted Shares Outstanding | 888.77% | 84.94% | 145.22% | 166.25% | 155.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |